[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"status-days":3,"theme-new-drugs":32},[4,18],{"date":5,"taiex_close":6,"taiex_chg":7,"taiex_chg_pct":8,"advancers":9,"decliners":10,"unchanged":11,"stocks":12,"turnover_sum":13,"margin_balance":14,"margin_chg":15,"short_balance":16,"short_chg":17},"2026-10-12",49301.96,-11.480000000003201,-0.00023279657634922568,868,916,158,1971,1044705369816,9174215,2895,175930,1165,{"date":19,"taiex_close":20,"taiex_chg":21,"taiex_chg_pct":22,"advancers":23,"decliners":24,"unchanged":25,"stocks":26,"turnover_sum":27,"margin_balance":28,"margin_chg":29,"short_balance":30,"short_chg":31},"2026-10-13",48341.31,-960.6500000000015,-0.019485026558781926,444,1337,161,1975,1306098703553,9070158,-104057,168869,-7061,{"id":33,"slug":34,"name":35,"category":36,"summary":39,"members":40,"ret_1d":41,"ret_5d":42,"ret_20d":43,"ret_60d":44,"up":45,"down":40,"flat":45,"mcap":46,"turnover":47,"spark":48,"verified_at":106,"updated_at":107,"as_of":19,"description":108,"facts":109,"drivers":119,"trends":123,"index_base_date":127,"published_at":128,"segments":129,"upstream":234,"downstream":241,"changes":242,"chips":243},55,"new-drugs","新藥研發",{"slug":37,"name":38},"biotech","生技醫療","從臨床試驗到授權與上市的新藥公司，營收與股價多由研發里程碑帶動。",7,-0.02604453744683346,0.009861385314756221,0.016705909767039673,-0.09406710009544228,0,565341903911.6,1542435658,[49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,64,80,81,82,83,82,84,85,86,87,88,58,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105],34.04,34.06,34.08,34.12,33.9,33.57,33.46,32.38,31.64,30.79,30.85,32.3,32.65,33.13,32.81,32.6,33.38,33.88,33.55,33.92,33.42,32.82,32.77,32.54,33.34,33.8,33.2,33.05,33.96,33.75,33.45,32.44,32.29,31.89,31.95,32.5,32.08,31.63,30.84,30.63,31,31.57,31.22,31.59,31.61,31.88,31.53,32.12,32.75,32.23,31.99,31.85,32.04,32.43,33.04,33.02,32.16,"2026-10-14","2026-10-14T04:39:47.967341+08:00","新藥開發要經過多期臨床試驗與主管機關審查，時間長、失敗率高。台灣新藥公司常見兩種模式：自己推進到上市銷售，或在臨床中期授權給國際藥廠換取簽約金、里程碑金與權利金。財報上研發費用大，獲利取決於少數產品，評估時要看產品線階段與現金水位。",[110,113,116],{"label":111,"value":112},"收入來源","產品銷售、授權金、里程碑金、權利金",{"label":114,"value":115},"關鍵事件","臨床結果、藥證審查、授權合約",{"label":117,"value":118},"觀察重點","產品線階段、現金水位",[120,121,122],"已上市產品的銷售成長","國際授權合作","癌症、罕病等未滿足醫療需求",[124,125,126],"授權交易以亞洲權利或全球權利分段進行","委託開發製造分工更細","法規審查與健保給付影響上市後銷售","2023-12-29","2026-10-14T04:39:48.306338+08:00",[130,223,228],{"id":131,"tier":132,"name":133,"description":134,"members":135},160,"upstream","新藥開發與臨床","自行開發或引進新藥並進行臨床試驗。",[136,154,167,178,189,201,213],{"code":137,"name":138,"role":139,"relevance":140,"note":141,"industry":142,"close":17,"chg_pct":143,"ret_5d":144,"ret_20d":145,"mcap":146,"turnover":147,"signals":148},"6446","藥華藥","leader","high","血液疾病新藥，已有上市產品","生技醫療業",-0.016877637130801593,-0.021008403361344352,-0.11742424242424243,492134794500,1315551970,[149,150,151,152,153],"rev_yoy","rev_yoy_3m","eps_yoy","trust_buy_5d","holders_up",{"code":155,"name":156,"role":157,"relevance":140,"note":158,"industry":142,"close":159,"chg_pct":160,"ret_5d":161,"ret_20d":162,"mcap":163,"turnover":164,"signals":165},"4743","合一","niche","傷口與皮膚新藥",47.55,-0.03451776649746208,0.009554140127388422,0.04390779363336983,22849367925,83204957,[151,166,153],"foreign_buy_5d",{"code":168,"name":169,"role":157,"relevance":140,"note":170,"industry":142,"close":171,"chg_pct":172,"ret_5d":173,"ret_20d":174,"mcap":175,"turnover":176,"signals":177},"4147","中裕","愛滋病抗體藥，已有上市產品",58.3,-0.036363636363636376,-0.028333333333333433,-0.0535714285714286,15927699919.999998,72544406,[],{"code":179,"name":180,"role":157,"relevance":140,"note":181,"industry":142,"close":182,"chg_pct":183,"ret_5d":184,"ret_20d":185,"mcap":186,"turnover":187,"signals":188},"4162","智擎","新藥開發與授權",56.5,-0.013961605584642212,0.027272727272727337,0.031021897810219023,8230784400,14152607,[149,151],{"code":190,"name":191,"role":157,"relevance":192,"note":193,"industry":142,"close":194,"chg_pct":195,"ret_5d":196,"ret_20d":197,"mcap":198,"turnover":199,"signals":200},"1760","寶齡富錦","mid","腎臟病用藥與保健品",54,-0.021739130434782594,0.0018552875695734272,-0.018181818181818077,4629906702,4998637,[149,151,166],{"code":202,"name":203,"role":204,"relevance":140,"note":205,"industry":142,"close":206,"chg_pct":207,"ret_5d":208,"ret_20d":209,"mcap":210,"turnover":211,"signals":212},"6550","北極星藥業-KY","challenger","癌症新藥開發",15.9,-0.027522935779816682,-0.01851851851851838,-0.19039113027409926,14227203930.000002,8240813,[151,166,153],{"code":214,"name":215,"role":204,"relevance":140,"note":205,"industry":142,"close":216,"chg_pct":217,"ret_5d":218,"ret_20d":219,"mcap":220,"turnover":221,"signals":222},"4174","浩鼎",55.8,-0.029565217391304355,0.20779220779220764,1.1338432122370938,7342146534.599999,43742268,[151],{"id":25,"tier":224,"name":225,"description":226,"members":227},"midstream","委託開發與生產","新藥公司多委託 CDMO 生產，見「CDMO 與學名藥」。",[],{"id":229,"tier":230,"name":231,"description":232,"members":233},162,"downstream","國際藥廠與醫療院所","授權對象與用藥端，多數不在台股。",[],[235],{"id":236,"slug":237,"name":238,"category":239,"ret_1d":240},56,"cdmo-generics","CDMO 與學名藥",{"slug":37,"name":38},-0.010119884584519796,[],[],{"members":40,"foreign_buy_count":244,"trust_buy_count":245,"holders_up_count":244},3,1]